{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:20:22Z","timestamp":1789179622291,"version":"build-2803163510"},"reference-count":74,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Sciences Foundation of China","doi-asserted-by":"crossref","award":["32471022"],"award-info":[{"award-number":["32471022"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Demyelinating diseases comprise a group of chronic and debilitating neurological disorders, with the destruction of the myelin sheath serving as the core pathological hallmark. The central pathogenesis involves immune-mediated damage to oligodendrocytes (Ols) and myelin breakdown, accompanied by a vicious cycle of neuroinflammation and impaired epigenetic repair. Current therapeutic strategies, including conventional immunomodulatory agents to targeted monoclonal antibodies, effectively control disease relapses but exhibit limited efficacy in promoting neural repair. Consequently, research focus is increasingly shifting towards neuroprotective and remyelination strategies. In this context, Emerging therapeutic promise stems primarily from two fronts: the advent of novel pharmaceuticals, such as remyelination-promoting drugs targeting oligodendrocyte maturation, interventions inhibiting epigenetic silencing, signal pathway inhibitors, and natural products derived from traditional Chinese medicine; the development of innovative technologies, including cell therapies, gene therapy, exosome and nanoparticle-based drug delivery systems, as well as extracellular protein degradation platforms. Nevertheless, drug development still faces challenges such as disease heterogeneity, limited blood\u2013brain barrier penetration, long-term safety, and difficulties in translating findings from preclinical models. Future efforts should emphasize precision medicine, multi-target synergistic therapies, and the development of intelligent delivery systems, with the ultimate goal of achieving a paradigm shift from delaying disability progression to functional neural reconstruction.<\/jats:p>","DOI":"10.3390\/ph18121835","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T08:49:22Z","timestamp":1764665362000},"page":"1835","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Advances in Therapeutics Research for Demyelinating Diseases"],"prefix":"10.3390","volume":"18","author":[{"given":"Jinhui","family":"Jiang","sequence":"first","affiliation":[{"name":"Zhejiang Key Laboratory of Organ Development and Regeneration, College of Life and Environmental Sciences, Hangzhou Normal University, Hangzhou 311121, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Sun","sequence":"additional","affiliation":[{"name":"Zhejiang Key Laboratory of Organ Development and Regeneration, College of Life and Environmental Sciences, Hangzhou Normal University, Hangzhou 311121, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Anatomy and Embryology, School of Basic Medical Sciences, Hangzhou Normal University, Hangzhou 311121, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenhui","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Anatomy and Embryology, School of Basic Medical Sciences, Hangzhou Normal University, Hangzhou 311121, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2045-4996","authenticated-orcid":false,"given":"Xiaofeng","family":"Zhao","sequence":"additional","affiliation":[{"name":"Zhejiang Key Laboratory of Organ Development and Regeneration, College of Life and Environmental Sciences, Hangzhou Normal University, Hangzhou 311121, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Anatomy and Embryology, School of Basic Medical Sciences, Hangzhou Normal University, Hangzhou 311121, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","article-title":"Multiple Sclerosis","volume":"372","author":"Compston","year":"2008","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.neurol.2018.01.368","article-title":"Classification and Diagnostic Criteria for Demyelinating Diseases of the Central Nervous System: Where Do We Stand Today?","volume":"174","author":"Mathey","year":"2018","journal-title":"Rev. Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1093\/brain\/awaa265","article-title":"Diagnostic Challenges in Chronic Inflammatory Demyelinating Polyradiculoneuropathy","volume":"143","author":"Eftimov","year":"2020","journal-title":"Brain J. Neurol."},{"key":"ref_4","first-page":"263","article-title":"Inflammatory Demyelinating Diseases of the Central Nervous System","volume":"145","author":"Lassmann","year":"2017","journal-title":"Handb. Clin. Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1126\/science.abj8222","article-title":"Longitudinal Analysis Reveals High Prevalence of Epstein-Barr Virus Associated with Multiple Sclerosis","volume":"375","author":"Bjornevik","year":"2022","journal-title":"Science"},{"key":"ref_6","unstructured":"International Multiple Sclerosis Genetics Consortium (2019). Multiple Sclerosis Genomic Map Implicates Peripheral Immune Cells and Microglia in Susceptibility. Science, 365, eaav7188."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.immuni.2022.02.008","article-title":"How Does Epstein-Barr Virus Trigger MS?","volume":"55","author":"Kuchroo","year":"2022","journal-title":"Immunity"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"eadn9980","DOI":"10.1126\/scitranslmed.adn9980","article-title":"Oligodendroglial Precursor Cells Modulate Immune Response and Early Demyelination in a Murine Model of Multiple Sclerosis","volume":"17","author":"Wang","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Wang, D., Zhang, T., Shao, Q., Wu, X., Zhao, X., Zhang, H., Wang, Y., Sun, J., Chang, X., and Zhu, K. (Cell Death Differ., 2025). GSDME-Mediated Pyroptosis in Microglia Exacerbates Demyelination and Neuroinflammation in Multiple Sclerosis: Insights from Humans and Cuprizone-Induced Demyelination Model Mice, Cell Death Differ., ahead of print.","DOI":"10.1038\/s41418-025-01537-0"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"21527","DOI":"10.1073\/pnas.2006566117","article-title":"Anacardic Acid Induces IL-33 and Promotes Remyelination in CNS","volume":"117","author":"Natarajan","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"508","DOI":"10.5603\/PJNNS.a2020.0069","article-title":"Pediatric Multiple Sclerosis\u2014Current Status of Epidemiology, Diagnosis and Treatment","volume":"54","author":"Brola","year":"2020","journal-title":"Neurol. Neurochir. Pol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"104753","DOI":"10.1016\/j.msard.2023.104753","article-title":"Epidemiology of Demyelinating Diseases in Mexico: A Registry-Based Study","volume":"75","author":"Rivas","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/WCO.0000000000000328","article-title":"Demyelinating Diseases in Asia","volume":"29","author":"Ochi","year":"2016","journal-title":"Curr. Opin. Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1177\/1352458508090666","article-title":"Patients with Multiple Sclerosis Resisted to Glucocorticoid Therapy: Abnormal Expression of Heat-Shock Protein 90 in Glucocorticoid Receptor Complex","volume":"14","author":"Matysiak","year":"2008","journal-title":"Mult. Scler."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1097\/WCO.0000000000000622","article-title":"Multiple Sclerosis: Clinical Aspects","volume":"31","author":"Oh","year":"2018","journal-title":"Curr. Opin. Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1517\/17425251003752715","article-title":"Glatiramer Acetate and the Glatiramoid Class of Immunomodulator Drugs in Multiple Sclerosis: An Update","volume":"6","author":"Johnson","year":"2010","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1146\/annurev-med-052814-023415","article-title":"Novel Agents for Relapsing Forms of Multiple Sclerosis","volume":"67","author":"Harel","year":"2016","journal-title":"Annu. Rev. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(09)61259-9","article-title":"Effect of Glatiramer Acetate on Conversion to Clinically Definite Multiple Sclerosis in Patients with Clinically Isolated Syndrome (PreCISe Study): A Randomised, Double-Blind, Placebo-Controlled Trial","volume":"374","author":"Comi","year":"2009","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S1474-4422(09)70226-1","article-title":"250 Microg or 500 Microg Interferon Beta-1b versus 20 Mg Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis: A Prospective, Randomised, Multicentre Study","volume":"8","author":"Filippi","year":"2009","journal-title":"Lancet Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1474-4422(08)70200-X","article-title":"Comparison of Subcutaneous Interferon Beta-1a with Glatiramer Acetate in Patients with Relapsing Multiple Sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] Study): A Multicentre, Randomised, Parallel, Open-Label Trial","volume":"7","author":"Mikol","year":"2008","journal-title":"Lancet Neurol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1212\/01.wnl.0000345970.73354.17","article-title":"Efficacy of Treatment of MS with IFNbeta-1b or Glatiramer Acetate by Monthly Brain MRI in the BECOME Study","volume":"72","author":"Cadavid","year":"2009","journal-title":"Neurology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1212\/01.wnl.0000343880.13764.69","article-title":"GLANCE: Results of a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study","volume":"72","author":"Goodman","year":"2009","journal-title":"Neurology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1177\/1352458507085759","article-title":"Glatiramer Acetate after Induction Therapy with Mitoxantrone in Relapsing Multiple Sclerosis","volume":"14","author":"Vollmer","year":"2008","journal-title":"Mult. Scler."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Roggeri, A., Schepers, M., Tiane, A., Rombaut, B., van Veggel, L., Hellings, N., Prickaerts, J., Pittaluga, A., and Vanmierlo, T. (2020). Sphingosine-1-Phosphate Receptor Modulators and Oligodendroglial Cells: Beyond Immunomodulation. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21207537"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/acn3.52017","article-title":"Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis Treatment: A Practical Review","volume":"11","author":"Coyle","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.msard.2019.08.009","article-title":"Effectiveness and Tolerability of Immunosuppressants and Monoclonal Antibodies in Preventive Treatment of Neuromyelitis Optica Spectrum Disorders: A Systematic Review and Network Meta-Analysis","volume":"35","author":"Huang","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"101967","DOI":"10.1016\/j.msard.2020.101967","article-title":"In MS: Immunosuppression Is Pass\u00e9","volume":"40","author":"Brod","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41582-021-00568-8","article-title":"Hope for Patients with Neuromyelitis Optica Spectrum Disorders\u2014From Mechanisms to Trials","volume":"17","author":"Pittock","year":"2021","journal-title":"Nat. Rev. Neurol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s13311-022-01222-x","article-title":"Therapeutic Monoclonal Antibody Therapies in Chronic Autoimmune Demyelinating Neuropathies","volume":"19","author":"Briani","year":"2022","journal-title":"Neurotherapeutics"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1080\/00207454.2016.1242587","article-title":"Monoclonal Antibody Therapy for Neuromyelitis Optica Spectrum Disorder: Current and Future","volume":"127","author":"Lin","year":"2017","journal-title":"Int. J. Neurosci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1007\/s43440-024-00642-0","article-title":"Multiple Sclerosis: A Narrative Overview of Current Pharmacotherapies and Emerging Treatment Prospects","volume":"76","author":"Olejnik","year":"2024","journal-title":"Pharmacol. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1007\/s00415-023-12007-3","article-title":"Key Characteristics of Anti-CD20 Monoclonal Antibodies and Clinical Implications for Multiple Sclerosis Treatment","volume":"271","author":"Delgado","year":"2024","journal-title":"J. Neurol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.tips.2025.05.001","article-title":"GPR17\u2014Orphan G Protein-Coupled Receptor with Therapeutic Potential","volume":"46","author":"Lewash","year":"2025","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1002\/cmdc.201600453","article-title":"The G Protein-Coupled Receptor GPR17: Overview and Update","volume":"11","author":"Marucci","year":"2016","journal-title":"ChemMedChem"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/path.6381","article-title":"Characterisation of GPR17-Expressing Oligodendrocyte Precursors in Human Ischaemic Lesions and Correlation with Reactive Glial Responses","volume":"265","author":"Raffaele","year":"2025","journal-title":"J. Pathol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/nn.2410","article-title":"The Oligodendrocyte-Specific G Protein-Coupled Receptor GPR17 Is a Cell-Intrinsic Timer of Myelination","volume":"12","author":"Chen","year":"2009","journal-title":"Nat. Neurosci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s12035-018-1146-1","article-title":"G-Protein-Coupled Receptor Gpr17 Expression in Two Multiple Sclerosis Remyelination Models","volume":"56","author":"Nyamoya","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Lu, C., Dong, L., Zhou, H., Li, Q., Huang, G., Bai, S.J., and Liao, L. (2018). G-Protein-Coupled Receptor Gpr17 Regulates Oligodendrocyte Differentiation in Response to Lysolecithin-Induced Demyelination. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-22452-0"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1586\/14737175.2016.1116387","article-title":"Remyelination Strategies in Multiple Sclerosis: A Critical Reflection","volume":"16","author":"Kipp","year":"2016","journal-title":"Expert Rev. Neurother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/nrd.2017.115","article-title":"Remyelination Therapies: A New Direction and Challenge in Multiple Sclerosis","volume":"16","author":"Plemel","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"100027","DOI":"10.1016\/j.molpha.2025.100027","article-title":"Enhancing Remyelination in Multiple Sclerosis via M1 Muscarinic Acetylcholine Receptor","volume":"107","author":"Chen","year":"2025","journal-title":"Mol. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e70235","DOI":"10.1111\/jnc.70235","article-title":"Ospemifene, a Selective Estrogen Receptor Modulator, Enhances Oligodendrocyte Myelination and Preserves Neurofunctions Against Injuries","volume":"169","author":"Liu","year":"2025","journal-title":"J. Neurochem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e2217635120","DOI":"10.1073\/pnas.2217635120","article-title":"MWF of the Corpus Callosum Is a Robust Measure of Remyelination: Results from the ReBUILD Trial","volume":"120","author":"Caverzasi","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"V\u00e9lez-Uriza, F., Ordaz, R.P., Garay, E., Cisneros-Mejorado, A.J., and Arellano, R.O. (2024). N-Butyl-\u03b2-Carboline-3-Carboxylate (\u03b2-CCB) Systemic Administration Promotes Remyelination in the Cuprizone Demyelinating Model in Mice. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-64501-x"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"105969","DOI":"10.1016\/j.phrs.2021.105969","article-title":"The Histone Deacetylase Inhibitor Belinostat Ameliorates Experimental Autoimmune Encephalomyelitis in Mice by Inhibiting TLR2\/MyD88 and HDAC3\/NF-\u03baB P65-Mediated Neuroinflammation","volume":"176","author":"Shen","year":"2022","journal-title":"Pharmacol. Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1021\/acschemneuro.1c00826","article-title":"HDAC3 Inhibitor RGFP966 Ameliorated Neuroinflammation in the Cuprizone-Induced Demyelinating Mouse Model and LPS-Stimulated BV2 Cells by Downregulating the P2X7R\/STAT3\/NF-\u03baB65\/NLRP3 Activation","volume":"13","author":"Sun","year":"2022","journal-title":"ACS Chem. Neurosci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2119\/molmed.2013.00159","article-title":"Low-Dose 5-Aza-2\u2032-Deoxycytidine Pretreatment Inhibits Experimental Autoimmune Encephalomyelitis by Induction of Regulatory T Cells","volume":"20","author":"Chan","year":"2014","journal-title":"Mol. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/jcp.24641","article-title":"Hypomethylating Agent 5-Aza-2\u2032-Deoxycytidine (DAC) Ameliorates Multiple Sclerosis in Mouse Models","volume":"229","author":"Mangano","year":"2014","journal-title":"J. Cell Physiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/s12974-018-1336-9","article-title":"Circulating EZH2-Positive T Cells Are Decreased in Multiple Sclerosis Patients","volume":"15","author":"Malhotra","year":"2018","journal-title":"J. Neuroinflamm."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"16480","DOI":"10.1021\/acs.jmedchem.4c01310","article-title":"Development of a First-in-Class DNMT1\/HDAC Inhibitor with Improved Therapeutic Potential and Potentiated Antitumor Immunity","volume":"67","author":"Chang","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa2415988","article-title":"Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis","volume":"392","author":"Fox","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/j.cell.2022.05.020","article-title":"Bone Marrow Hematopoiesis Drives Multiple Sclerosis Progression","volume":"185","author":"Shi","year":"2022","journal-title":"Cell"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Kalafatakis, I., Papagianni, F., Theodorakis, K., and Karagogeos, D. (2023). Nogo-A and LINGO-1: Two Important Targets for Remyelination and Regeneration. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24054479"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1038\/s41401-025-01492-z","article-title":"Gastrodin Promotes CNS Myelinogenesis and Alleviates Demyelinating Injury by Activating the PI3K\/AKT\/mTOR Signaling","volume":"46","author":"Shi","year":"2025","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/nrn917","article-title":"Why Does Remyelination Fail in Multiple Sclerosis?","volume":"3","author":"Franklin","year":"2002","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Dedoni, S., Scherma, M., Camoglio, C., Siddi, C., Dazzi, L., Puliga, R., Frau, J., Cocco, E., and Fadda, P. (2023). An Overall View of the Most Common Experimental Models for Multiple Sclerosis. Neurobiol. Dis., 184.","DOI":"10.1016\/j.nbd.2023.106230"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"273","DOI":"10.5114\/fn.2023.129066","article-title":"Astragaloside IV Inhibits Experimental Autoimmune Encephalomyelitis by Modulating the Polarization of Both Microglia\/Macrophages and Astrocytes","volume":"61","author":"Yu","year":"2023","journal-title":"Folia Neuropathol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.taap.2018.10.024","article-title":"Astragaloside IV Regulates Differentiation and Induces Apoptosis of Activated CD4+ T Cells in the Pathogenesis of Experimental Autoimmune Encephalomyelitis","volume":"362","author":"Yang","year":"2019","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"119748","DOI":"10.1016\/j.jep.2025.119748","article-title":"Tripterygium Glycoside Tablets and Triptolide Alleviate Experimental Autoimmune Encephalomyelitis Mice Involving the PACAP\/cAMP Signaling Pathway","volume":"347","author":"Wang","year":"2025","journal-title":"J. Ethnopharmacol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.3892\/mmr.2016.5431","article-title":"Tanshinone IIA Attenuates Experimental Autoimmune Encephalomyelitis in Rats","volume":"14","author":"Yan","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejphar.2015.12.014","article-title":"Treatment with Tanshinone IIA Suppresses Disruption of the Blood-Brain Barrier and Reduces Expression of Adhesion Molecules and Chemokines in Experimental Autoimmune Encephalomyelitis","volume":"771","author":"Yang","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jconrel.2022.12.026","article-title":"Resveratrol-Loaded Macrophage Exosomes Alleviate Multiple Sclerosis through Targeting Microglia","volume":"353","author":"Zheng","year":"2023","journal-title":"J. Control. Release"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1007\/s13311-023-01378-0","article-title":"Nanoparticles Enhance Solubility and Neuroprotective Effects of Resveratrol in Demyelinating Disease","volume":"20","author":"Shamsher","year":"2023","journal-title":"Neurotherapeutics"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.neuroscience.2024.07.021","article-title":"Olig2-Enriched Exosomes: A Novel Therapeutic Approach for Cuprizone-Induced Demyelination","volume":"555","author":"Li","year":"2024","journal-title":"Neuroscience"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"122668","DOI":"10.1016\/j.lfs.2024.122668","article-title":"Potential Therapeutic and Diagnostic Approaches of Exosomes in Multiple Sclerosis Pathophysiology","volume":"347","author":"Hasaniani","year":"2024","journal-title":"Life Sci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1111\/1440-1681.13710","article-title":"The Role and Therapeutic Applications of Exosomes in Multiple Sclerosis Disease","volume":"49","author":"Komlakh","year":"2022","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s43094-025-00809-3","article-title":"Glatiramer\u2013Diclofenac Nanocomplex Enhances Remyelination in a Mouse Model of Multiple Sclerosis","volume":"11","author":"Aldhabi","year":"2025","journal-title":"Future J. Pharm. Sci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1021\/acs.biochem.2c00310","article-title":"Targeted Protein Degradation via Lysosomes","volume":"62","author":"Paudel","year":"2023","journal-title":"Biochemistry"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"123313","DOI":"10.1016\/j.jns.2024.123313","article-title":"Early Deterioration of CIDP Following Transition from IVIG to FcRn Inhibitor Treatment","volume":"468","author":"Levine","year":"2025","journal-title":"J. Neurol. Sci."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"100704","DOI":"10.1016\/j.medj.2025.100704","article-title":"Anti-BCMA CAR-T Cell Therapy in Relapsed\/Refractory Chronic Inflammatory Demyelinating Polyneuropathy","volume":"6","author":"Dong","year":"2025","journal-title":"Med"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1631\/jzus.B2300790","article-title":"Olig2+ Single-Colony-Derived Cranial Bone-Marrow Mesenchymal Stem Cells Achieve Improved Regeneration in a Cuprizone-Induced Demyelination Mouse Model","volume":"25","author":"Peng","year":"2024","journal-title":"J. Zhejiang Univ. Sci. B"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"146572","DOI":"10.1016\/j.brainres.2019.146572","article-title":"Gene Therapy Approaches Targeting Schwann Cells for Demyelinating Neuropathies","volume":"1728","author":"Sargiannidou","year":"2020","journal-title":"Brain Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"9883","DOI":"10.1038\/s41467-025-66058-3","article-title":"Characterizing and Controlling CRISPR Repair Outcomes in Nondividing Human Cells","volume":"16","author":"Ramadoss","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.stem.2025.03.009","article-title":"Harnessing Human iPSC-Microglia for CNS-Wide Delivery of Disease-Modifying Proteins","volume":"32","author":"Chadarevian","year":"2025","journal-title":"Cell Stem Cell"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/12\/1835\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T05:28:05Z","timestamp":1764739685000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/12\/1835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":74,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["ph18121835"],"URL":"https:\/\/doi.org\/10.3390\/ph18121835","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]}}}